Mayne Pharma enters Scheme Implementation Deed with Cosette
Released
Released
Announcement PDF
ASX Announcement
MAYNE PHARMA ENTERS INTO A SCHEME IMPLEMENTATION
DEED WITH COSETTE PHARMACEUTICALS, INC
•
Acquisition price of A$7.40 per share in cash.
•
Consideration represents a significant premium to the pre-announcement share price.
•
The Mayne Pharma Board unanimously recommends that Mayne Pharma shareholders
vote in favour of the Scheme in the absence of a Superior Proposal and subject to the
Independent Expert concluding (and continuing to conclude) that the Scheme is in the
best interests of Mayne Pharma shareholders.
21 February 2025, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX), (Mayne Pharma)
announces that it has entered into a scheme implementation deed with Cosette Pharmaceuticals,
Inc. (Cosette) under which Cosette has agreed to acquire 100% of the shares in Mayne Pharma by
way of a Scheme of Arrangement (Scheme) at a price of A$7.40 per share (Scheme Consideration).
Cosette is a US based pharmaceutical company with a portfolio of products in women’s health
and dermatology. Cosette has a history in the manufacturing of complex dosage forms including
topical creams, ointments, oral liquids/solutions and suppositories. Cosette has corporate and
manufacturing facilities in New Jersey and North Carolina and is supported by 350 plus team
members across all functional areas. Cosette is backed by Avista Healthcare Partners, a
healthcare focused private equity firm, and funds managed by Hamilton Lane, a private markets
investment management firm (Nasdaq: HLNE).
Overview of the Scheme
The Scheme Consideration of A$7.40 per share values Mayne Pharma’s equity at approximately
A$672 million1 and represents a premium of:
• 37% to Mayne Pharma’s closing share price as at 20 February 2025;
• 42% premium to the 30-day volume weighted average price (VWAP);
• 50% premium to the 90-day VWAP; and
• 57% premium to the 180-day VWAP.
The Scheme is fully funded and subject to limited customary conditions, including various
regulatory approvals, approval by Mayne Pharma shareholders at the Scheme meeting, with a
Scheme booklet and an independent expert’s report to be provided to Mayne Pharma
shareholders, and Court approval.
1
Based on the combined value of i) approximately 83.1 million Mayne Pharma shares, taking into account Mayne
Pharma’s ordinary shares on issue and equity incentives on issue or proposed to be issued, and ii) the value of the
Mayne Pharma Convertible Notes to be acquired by Cosette.
ASX Announcement
Mayne Pharma Chair, Frank Condella, said:
“We are pleased that Cosette has recognised significant value in Mayne Pharma, particularly in
our women’s health and dermatology businesses, and the offer provides shareholders with the
opportunity to receive cash value at a significant premium.
The Board believes that the proposed transaction is in line with the Board’s priority to deliver
value to our shareholders, and also provides significant benefits for our broader stakeholders.”
Mayne Pharma CEO, Shawn Patrick O’Brien, said:
“Today marks a pivotal moment in Mayne’s journey to improve patient access to life-enhancing
medications. Attracting an offer from a strategic buyer who is active in the US Dermatology and
Women’s Health markets, such as Cosette, reflects the excellent work our teams have been doing
to strengthen our company over the last year and more. Having broadened our portfolio in
Dermatology and Women’s Health, and improved patient access through a refined US channel
strategy, we have executed against our corporate strategies with precision. As we enter this new
chapter, we do so as a stronger, more agile company.”
Recommendation
The Mayne Pharma Board unanimously recommends that Mayne Pharma shareholders vote in
favour of the Scheme, in the absence of a Superior Proposal and subject to an independent expert
concluding (and continuing to conclude) that the Scheme is in the best interests of Mayne Pharma
shareholders.
Subject to these qualifications, each Mayne Pharma Director has confirmed that they intend to
vote any shares that they hold or control in favour of the Scheme.
Shareholder support
Mayne Pharma’s two largest shareholders, Viburnum Funds and Mr Bruce Mathieson, who
currently collectively own 14.1% of the issued ordinary shares of the Company have both notified
Mayne Pharma that they intend to vote all shares held by them on the record date for the Scheme
Meeting in favour of the proposed transaction in the absence of a superior proposal.
Furthermore, Rubric Capital, the owner of 100% of the Mayne Pharma Convertible Notes issued
31 December 2022 has agreed to divest its Convertible Notes at Completion of the Scheme to
Cosette for a value equivalent to the amount payable to Rubric had the Convertible Notes been
converted by Rubric to Mayne Pharma shares and acquired at the Scheme Consideration.
Overview of the Scheme Implementation Deed (SID)
The implementation of the Scheme is subject to conditions customary for a transaction of this
nature, including:
• Various regulatory approvals as set out in the SID, including by the Foreign Investment
Review Board;
• Mayne Pharma shareholder approval;
Page 2
ASX Announcement
•
•
•
•
•
The independent expert concluding (and continuing to conclude) that the Scheme is in
the best interests of Mayne Pharma shareholders;
Approval by the Court;
No restraints being enacted in the jurisdictions in which Mayne Pharma operates
preventing implementation of the Scheme;
No Mayne Pharma material adverse change; and
No prescribed occurrences.
The Scheme is not subject to any financing condition.
All of the obligations of the transaction with Cosette, including deal protections, termination
rights and break fees, are agreed and set out in the SID attached to this announcement.
Indicative timetable and next steps
Mayne Pharma shareholders do not need to take any action at this stage.
A Scheme Booklet containing information relating to the Scheme, the reasons for the Directors’
recommendation, the Independent Expert’s Report opining on whether the Scheme is in the best
interests of Mayne Pharma shareholders and details of the Scheme Meeting will be dispatched to
shareholders in due course in advance of the Scheme Meeting.
Mayne Pharma shareholders will be given the opportunity to vote on the Scheme at a Scheme
Meeting, which is currently expected to be held in late April to early May 2025. If the Scheme is
approved by Mayne Pharma shareholders and the other conditions precedent are satisfied or
waived, the Scheme is expected to be implemented in late May to early June 2025.
These dates are indicative, subject to change and conditional on (among other things) regulatory
approval, and shareholder approval at the Scheme Meeting.
Event
Expected Date
First Court Hearing
Dispatch of Scheme Booklet to Mayne Pharma Shareholders
Scheme Meeting
Second Court Date
Effective Date
Implementation Date
Late March 2025
Late March 2025
Late April to early May 2025
Early to mid May 2025
Mid May 2025
Late May to early June 2025
Mayne Pharma is being advised by Jefferies Australia as financial adviser and Gilbert + Tobin and
Arnold & Porter as legal advisers.
Cosette is being advised by Santander US Capital Markets LLC and UBS AG as financial advisers
and Corrs Chambers Westgarth and Ropes & Gray LLP as legal advisers.
Page 3
ASX Announcement
For further information contact:
Dr Tom Duthy
+61 402 493 727
ir@maynepharma.com
Authorised for release to the ASX by the Board of Directors
About Mayne Pharma
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising
novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne
Pharma is a leader in dermatology and women’s health and also provides contract development
and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of
innovation and success in developing new oral drug delivery systems. These technologies have
been successfully commercialised in numerous products that continue to be marketed around
the world. To learn more about Mayne Pharma, please visit maynepharma.com.
About Cosette
Cosette Pharmaceuticals, Inc. is a U.S.-based pharmaceutical company with a portfolio of
products in women’s health and dermatology. Cosette has a history in the manufacturing of
complex dosage forms including topical creams, ointments, oral liquids/solutions and
suppositories. Cosette has corporate and manufacturing facilities in New Jersey and North
Carolina and is supported by 350+ team members across all functional areas. Cosette is backed
by Avista Healthcare Partners, a healthcare focused private equity firm, and funds managed by
Hamilton Lane, a private markets investment management firm (Nasdaq: HLNE). For more
information, please visit www.cosettepharma.com or follow Cosette on LinkedIn.
Page 4
Mayne
Mayne Pharma
Pharma Group
Group Limited
Limited
Cosette
Cosette Pharmaceuticals,
Pharmaceuticals, Inc.
Inc.
Scheme
scheme
Implementation
Implementation Deed
Deed
3470-1435-1155v25
3470-1435-1155v25
148655978_21
148655978
_21
Corrs Chambers Westgarth
Contents
1
2
3
4
5
Definitions and Interpretation
1
1.1
1.2
1.3
1.4
1.5
1.6
1.7
1
18
19
19
19
19
20
Definitions
Interpretation
Business Day
Best and reasonable endeavours
Consents or approvals
Knowledge, belief or awareness of Mayne
Listing requirements included as law
Agreement to proceed with Scheme
20
2.1
2.2
20
20
Mayne to propose the Scheme
Cosette to assist
Conditions Precedent
20
3.1
3.2
3.3
3.4
3.5
3.6
3.7
3.8
20
22
23
25
26
27
27
28
Conditions Precedent
Best endeavours and co-operation
Regulatory Approvals
Benefit and Waiver of Conditions Precedent
Notifications
Scheme voted down because of Headcount Test
Failure of Conditions Precedent
Certificates in relation to Conditions Precedent
Transaction Steps
29
4.1
4.2
4.3
4.4
4.5
4.6
29
29
29
29
30
30
Scheme
Cosette Sub
Scheme Consideration
Provision of Scheme Consideration
Mayne Convertible Securities
No amendment to Scheme without consent
Implementation
30
5.1
5.2
5.3
5.4
30
35
35
39
Mayne's obligations
Appeal process
Cosette’s obligations
Appointment of directors
6
Integration Committee
39
7
Conduct of Business and Requests for Access
40
7.1
7.2
7.3
7.4
7.5
7.6
40
43
45
46
48
48
Conduct of Mayne business
Permitted conduct
Access to information and co-operation
Co-operation in relation to Transaction financing
Third Party consents
Directors' and officers' insurance and indemnities
3470-1435-1155v25
Scheme Implementation Deed
148655978_21
page i
Corrs Chambers Westgarth
8
9
10
11
12
13
14
Mayne Board Recommendation
49
8.1
8.2
8.3
49
50
51
Recommendation and Voting Intention Statement
Withdrawal of Recommendation or Voting Intention Statement
Confirmation
Representations and warranties
51
9.1
9.2
9.3
9.4
9.5
9.6
9.7
51
51
53
53
53
53
54
Cosette Representations and Warranties
Mayne Representations and Warranties
Timing of representations and warranties
Survival of representations
Survival of indemnities
Notification obligation
No representation or reliance
Releases
54
10.1 Mayne Parties
10.2 Cosette Parties
54
54
Public Announcements
55
11.1 Announcement of the Transaction
11.2 Other public announcements
55
55
Exclusivity
55
12.1
12.2
12.3
12.4
12.5
12.6
12.7
55
55
56
57
57
58
60
No current discussions regarding a Competing Proposal
No-shop, no talk and no due diligence
Limitations to no-talk and no due diligence
Notification by Mayne
Compliance with law
Cosette matching right
Normal provision of information
Mayne Break Fee
60
13.1
13.2
13.3
13.4
13.5
13.6
13.7
60
61
62
62
63
63
63
Background
Payment of Mayne Break Fee
Payment conditions
Timing of payment
Nature of payment
Compliance with law
Limitation of liability
Cosette Break Fee
64
14.1
14.2
14.3
14.4
14.5
14.6
14.7
64
65
65
65
66
66
67
Background
Payment of Cosette Break Fee
Timing of payment
Nature of payment
Compliance with law
Limitation of liability
Claims under the Deed Poll
3470-1435-1155v25
Scheme Implementation Deed
148655978_21
page ii
Corrs Chambers Westgarth
15
Termination
67
15.1 General rights
15.2 Effect of termination
15.3 Termination by written agreement
67
68
68
16
Confidentiality
68
17
GST
69
17.1
17.2
17.3
17.4
17.5
18
Recovery of GST
Liability net of GST
Adjustment events
Survival
Interpretation
69
69
69
69
69
Withholding
69
18.1 Foreign resident capital gains tax withholding
69
19
Notices
71
20
General provisions
72
20.1 Amendment
20.2 Assignment
20.3 Costs and stamp duty
20.4 Third party beneficiary
20.5 Execution and Counterparts
20.6 Entire agreement
20.7 Further assurances
20.8 Governing law and jurisdiction
20.9 Process agent
20.10 No merger
20.11 No waiver
20.12 Severability of provisions
20.13 Relationship of the parties
20.14 Remedies cumulative
20.15 Exercise of rights
20.16 Debt financing matters
72
72
72
72
73
73
73
73
73
74
74
74
74
74
74
74
Schedule 1 - Cosette Representations and Warranties
77
Schedule 2 - Mayne Representations and Warranties
82
Schedule 3 - Mayne Prescribed Occurrences
86
Schedule 4 - Timetable
88
Annexure A - Form of Scheme
90
Annexure B - Form of Deed Poll
105
3470-1435-1155v25
Scheme Implementation Deed
148655978_21
page iii
Corrs Chambers Westgarth
Date 20 February 2025
Parties
Mayne Pharma Group Limited ACN 115 832 963 of 1538 Main North Road, Salisbury
South, South Australia 5106, Australia (Mayne)
Cosette Pharmaceuticals, Inc. a Delaware corporation of 200 Crossing Boulevard,
Bridgewater, New Jersey 08807 (Cosette)
Background
A
The parties have agreed that Cosette Sub will acquire all of the Scheme
Shares by means of a scheme of arrangement under Part 5.1 of the
Corporations Act between Mayne and the Scheme Shareholders.
B
Mayne has agreed to propose and implement the Scheme, and Cosette has
agreed to assist Mayne to propose and implement the Scheme, on the terms of
this deed.
Agreed terms
1
Definitions and Interpretation
1.1
Definitions
The following definitions apply unless the context requires otherwise.
280G Analysis
Has the meaning given in clause 5.1(v).
Adviser
In relation to an entity, a financial, corporate, legal,
tax, or other expert adviser or consultant, who
provides advisory or consultancy services in a
professional capacity in the ordinary course of its
business and has been engaged in that capacity in
connection with the Transaction by the entity.
Antitrust Laws
The Sherman Antitrust Act of 1890, as amended, the
Clayton Antitrust Act of 1914, as amended, the HSR
Act, the Federal Trade Commission Act of 1914, as
amended, and all other U.S., Australian and foreign,
federal, state and local statutes, rules, regulations,
orders, decrees, administrative and judicial doctrines
and other Laws that are designed or intended to
prohibit, restrict or regulate actions having the
3470-1435-1155v25
Scheme Implementation Deed
148655978_21
page 1
Corrs Chambers Westgarth
purpose or effect of monopolization or restraint of
trade or lessening of competition through merger or
acquisition.
ASIC
The Australian Securities and Investments
Commission.
Associate
Has the meaning set out in sections 12(2)(b) and (c)
of the Corporations Act, where for the purposes of
section 12, the 'designated body' is Mayne.
ASX
ASX Limited (ABN 98 008 624 691) or, as the context
requires, the financial market known as 'ASX'
operated by ASX Limited.
ASX Listing Rules
The official listing rules of ASX.
Business Day
Any day that is each of the following:
(a)
a Business Day within the meaning given in the
ASX Listing Rules; and
(b)
a day that banks are open for business in each
of Sydney, New South Wales, New York,
United States of America and London, United
Kingdom.
provided that where this deed refers to a date that is
a certain number of days before the Second Court
Date only paragraph (a) of this definition shall apply.
CGT Withholding
Amount
Has the meaning given in clause 18.1(a).
Claim
In relation to a person, any claim, demand, legal
proceedings or cause of action (including any claim,
demand, legal proceedings or cause of action) made
or brought by or against the person, however, arising
and whether present, unascertained, immediate,
future or contingent.
Communications
Has the meaning given in clause 3.3(a)(iv).
Competing
Proposal
Any expression of interest, proposal, offer,
transaction, agreement or arrangement (whether
existing before, on or after the date of this deed) by or
with any person pursuant to which, if the expression
of interest, proposal, offer, transaction, agreement or
arrangement is entered into or completed
substantially in accordance with its terms, would or
could reasonably be expected to mean that:
(a)
3470-1435-1155v25
Scheme Implementation Deed
148655978_21
a Third Party will (either alone or together with
any Associate) directly or indirectly:
page 2
Corrs Chambers Westgarth
(b)
(i)
acquire a relevant interest in, or acquire
or obtain a right to acquire a legal,
beneficial, economic or voting interest in
(including by way of equity swap, contract
for difference or similar transaction or
arrangement), or control of, 20% or more
of the securities in Mayne or any material
operating subsidiary of Mayne (on a fully
diluted basis);
(ii)
acquire, obtain a right to acquire, become
the holder of, or otherwise obtain a legal,
beneficial or economic interest in, or
control of, all or a substantial part of the
assets or business of Mayne or the
Mayne Group (taken as a whole);
(iii)
otherwise acquire control (within the
meaning of section 50AA of the
Corporations Act, but disregarding
subsection 50AA(4) of the Corporations
Act) of Mayne or any material operating
subsidiary of Mayne; or
(iv)
otherwise acquire, become stapled to, or
merge or amalgamate with, Mayne or any
material operating subsidiary of Mayne;
or
a party would be required to abandon or
otherwise fail to proceed with the Transaction,
whether by way of takeover offer or bid, members’ or
creditors’ scheme of arrangement, shareholder
approved acquisition, reverse takeover, capital
reduction, buy back, sale or purchase of shares, other
securities or assets, assignment of assets and
liabilities, incorporated or unincorporated joint
venture, dual-listed company (or other synthetic
merger), deed of company arrangement, any debt for
equity arrangement or other transaction or
arrangement.
Conditions
Precedent
Has the meaning given in clause 3.1.
Confidentiality
Agreement
The mutual confidentiality agreement between
Cosette and Mayne dated 6 September 2024.
Convertible Note
Deed Poll
The convertible note deed poll executed by Mayne in
favour of Rubric Capital Management LP dated 29
3470-1435-1155v25
Scheme Implementation Deed
148655978_21
page 3
Corrs Chambers Westgarth
December 2022.
Convertible Notes
Unsecured convertible notes issued by Mayne on 31
December 2022 to Rubric Capital Management LP.
Corporations Act
The Corporations Act 2001 (Cth), as amended by any
applicable ASIC class order, ASIC legislative
instrument or ASIC relief.
Corporations
Regulations
The Corporations Regulations 2001 (Cth).
Cosette Break Fee
A$6,718,788.50.
Cosette
Counterproposal
Has the meaning given in clause 12.6(a)(ii)(C).
Cosette Deal Team
The persons as agreed in writing between Mayne and
Cosette prior to the date of this deed.
Cosette Group
Cosette and each of its Related Bodies Corporate. A
reference to a member of the Cosette Group is a
reference to Cosette or any such Related Bodies
Corporate.
Cosette
Information
Information regarding the Cosette Group provided by
Cosette or any of its Advisers to Mayne in writing for
inclusion in the Scheme Booklet as required by
clauses 5.3(a) and 5.3(g), but excluding (for the
avoidance of any doubt) the Mayne Information or the
Independent Expert's Report and any information
regarding the taxation effect of the Transaction on
Scheme Shareholders prepared by an external
adviser to Mayne.
Cosette Party
Any member of the Cosette Group or any officer,
employee or Adviser of any of them.
Cosette
Representation
and Warranty
A representation and warranty of Cosette set out in
schedule 1.
Cosette Revolver
Consent Letter
(Santander)
The executed letter headed ‘Project Monarch USD 15
million Incremental Revolving Facility Commitment
Letter’ dated on or about the date of this deed
between Banco Santander, S.A., New York Branch
and Cosette.
Cosette Revolver
Consent Letter
(UBS)
The executed letter headed ‘Project Monarch
Consent Letter’ dated on or about the date of this
deed between UBS AG, Stamford Branch and
Cosette.
Cosette Revolver
The ‘Existing Credit Agreement’ as defined in the
3470-1435-1155v25
Scheme Implementation Deed
148655978_21
page 4
Corrs Chambers Westgarth
Facility Agreement
Cosette Revolver Consent Letter (and for the
avoidance of doubt, includes the ‘Amended Credit
Agreement’ under and as defined in the Cosette
Revolver Consent Letter).
Cosette Sub
Has the meaning given in clause 4.2(a).
Court
The Supreme Court of New South Wales or any other
court of competent jurisdiction under the Corporations
Act as agreed to in writing between the parties.
Data Protection
Laws
Any Laws applicable to the Mayne Group relating to
the Processing of data (including Personal
Information), data privacy, data security and data
breach notification.
Data Room
Materials
(a)
All documentation contained in the electronic
data room; and
(b)
the written responses by or on behalf of the
Mayne Group or its Representatives (and any
documents provided together with those
responses) to the questions raised by the
Cosette Group or its Representatives, including
any attachments to such responses, before the
date of this deed,
in each case, as evidenced by the data room index
agreed in writing between the parties on the date of
this deed.
D&O Policy
Has the meaning given in clause 7.6(b).
Debt Documents
(a)
The executed letter headed ‘Project Monarch
Commitment Letter’ dated on or about the date
of this deed between, amongst others, HAYFIN
DLF V LUXCO S.À R.L. and Cosette
Pharmaceuticals and accompanying term
sheets;
(b)
the Cosette Revolver Consent Letter (UBS);
and
(c)
the Cosette Revolver Consent Letter
(Santander),
copies of which were provided to Mayne prior to
execution of this deed.
Debt Financing
3470-1435-1155v25
Scheme Implementation Deed
148655978_21
The debt financing provided or intended to be
provided in connection with the Scheme to Cosette or
a Subsidiary of Cosette as contemplated by the Debt
Documents.
page 5
Corrs Chambers Westgarth
Debt Financing
Sources
The persons that have committed to provide the Debt
Financing or have otherwise entered into agreements
in connection with the Debt Financing, including any
lenders, arrangers, administrative agents or trustees
part of the Debt Financing, together with the former,
current and future affiliates, officers, directors,
employees, attorneys, partners (general or limited),
controlling parties, advisors, members, managers,
accountants, consultants, agents, representatives
and funding sources of each of the foregoing involved
in the Debt Financing, and their successors and
assigns.
Deed Poll
A deed poll in favour of all Scheme Shareholders in
the form of annexure B (or such other form agreed to
in writing between the parties to this deed).
Disclosing Party
Has the meaning given in clause 3.3(d).
Disclosure Letter
The letter identified as such provided by Mayne to
Cosette and countersigned by Cosette on or prior to
the date of this deed and any document identified in
that letter as having been disclosed to Cosette
subject to such document having been Fairly
Disclosed in the Due Diligence Material on or prior to
the date of that letter.
Due Diligence
Material
(a)
The Data Room Materials;
(b)
the Disclosure Letter; and
(c)
any other information made available by Mayne
or its Representatives to Cosette Group or its
Representatives prior to execution of this deed
which is agreed between the parties in writing
on the date of this deed.
EBITDA
In respect of a financial period, the underlying
earnings before interest, taxes, depreciation and
amortisation for the consolidated Mayne Group using
the same methodology as in the Mayne Group’s fullyear financial report for the financial year ending 30
June 2024.
Effective
The coming into effect under section 411(10) of the
Corporations Act of the order of the Court made
under section 411(4)(b) of the Corporations Act in
relation to the Scheme, but in any event at no time
before an office copy of the order of the Court is
lodged with ASIC.
Effective Date
The date on which the Scheme becomes Effective.
3470-1435-1155v25
Scheme Implementation Deed
148655978_21
page 6
Corrs Chambers Westgarth
End Date
The date that is nine months after the date of this
deed or such other date as may be agreed in writing
between Mayne and Cosette.
Entity Declaration
Has the meaning given in clause 18.1(c)(i).
Equity
Commitment
Letter
The executed equity commitment letter dated on or
before the date of this deed by and among the
Sponsors and Cosette.
Exclusivity Period
The period from and including the date of this deed to
the earlier of:
(a)
the termination of this deed in accordance with
its terms;
(b)
the End Date; and
(c)
the Effective Date.
Fairly Disclosed
In relation to a matter, such matter being disclosed in
sufficient detail so as to enable a reasonable and
sophisticated person who is experienced in
transactions similar to the Transaction to identify the
nature, substance and scope of the relevant matter,
event or circumstance.
FATA
The Foreign Acquisitions and Takeovers Act 1975
(Cth).
FDA
The United States Food and Drug Administration.
Financing
Agreements
Has the meaning given in clause 5.3(l)(i).
FIRB
The Australian Foreign Investment Review Board.
First Court Date
The first day of hearing of an application made to the
Court by Mayne for orders, under section 411(1) of
the Corporations Act, convening the Scheme Meeting
or, if the hearing of such application is adjourned for
any reason, means the first day of the adjourned
hearing.
Government
Agency
Any Australian or foreign government or
governmental, semi-governmental or judicial entity or
authority. It also includes any government minister
(and their delegate), any self-regulatory organisation
established under statute or any securities exchange
and, for the avoidance of doubt, includes ASIC, ASX,
FIRB, ACCC and equivalent bodies in jurisdictions
outside Australia and the US Federal Trade
Commission.
3470-1435-1155v25
Scheme Implementation Deed
148655978_21
page 7
Corrs Chambers Westgarth
GST
Goods and services tax or similar value added tax
levied or imposed in Australia under the GST Law or
otherwise on a supply.
GST Act
The A New Tax System (Goods and Services Tax)
Act 1999 (Cth).
GST Amount
Has the meaning given in clause 17.1.
GST Law
Has the same meaning as in the GST Act.
Headcount Test
The requirement under section 411(4)(a)(ii)(A) of the
Corporations Act that the resolution to approve the
Scheme at the Scheme Meeting is passed by a
majority in number of Mayne Shareholders present
and voting, either in person or by proxy.
Healthcare Laws
All laws of any Governmental Agency pertaining to
healthcare regulatory matters applicable to the Mayne
Group’s operations, products, and assets.
HSR Act
The United States Hart-Scott-Rodino Antitrust
Improvements Act of 1976, as amended, and the
rules promulgated thereunder.
Implementation
Date
The fifth Business Day after the Scheme Record Date
or such other date agreed to in writing between
Cosette and Mayne.
Independent
Expert
An independent expert to be engaged by Mayne to
express an opinion on whether the Scheme is in the
best interests of Mayne Shareholders.
Independent
Expert's Report
The report from the Independent Expert
commissioned by Mayne for inclusion in the Scheme
Booklet, and any update to such report that the
Independent Expert issues prior to the Scheme
Meeting.
Insolvency Event
In the case of any entity:
3470-1435-1155v25
Scheme Implementation Deed
148655978_21
(a)
it ceases, suspends, or threatens to cease or
suspend the conduct of all or a substantial part
of its business or disposes of or threatens to
dispose of all or a substantial part of its assets;
(b)
it stops or suspends, or threatens to stop or
suspend, payment of all or a class of its debts
when they fall due;
(c)
it is, or under legislation is presumed or taken
to be, insolvent (other than as the result of a
failure to pay a debt or Claim the subject of a
good faith dispute);
page 8
Corrs Chambers Westgarth
(d)
it has an administrator, controller or similar
officer appointed, or any step preliminary to the
appointment of such an officer is taken;
(e)
an application or an order is made, proceedings
are commenced, or a resolution is passed (and
in the case of an application, it is not stayed,
withdrawn or dismissed within 30 days) for:
(f)
(i)
its winding up, dissolution or
administration; or
(ii)
it entering into an arrangement,
compromise or composition with, or
assignment for, the benefit of its creditors
or a class of them;
a:
(i)
receiver, receiver and manager,
administrative receiver or similar officer is
appointed to;
(ii)
security interest becomes enforceable or
is enforced over; or
(iii)
distress, attachment or other execution is
levied or enforced or applied for over,
all or a substantial part of its assets; or
(g)
anything analogous to anything referred to in
the above paragraphs, or which has
substantially similar effect, occurs with respect
to it, including under any foreign law.
Integration
Committee
Has the meaning given in clause 6(a).
IT Systems
The computer systems, networks, hardware, digital
storage media, applications and software of the
Mayne
Share your feedback
Discover